Movement Alert｜10x Genomics, Inc. Falls 4.26% in Regular Trading, Post-Earnings Target Cuts Continue to Weigh on Valuation

Market Focus00:17

On November 14, 10x Genomics, Inc. fell 4.26% in Regular Trading, trading at $56.57 per share, with turnover of $35.86 million.

The move followed continued market digestion of the company’s latest quarterly report, where results and full-year revenue guidance topped expectations, but several institutions lowered their price targets after earnings, sustaining valuation pressure on the shares.

In the latest reported quarter, 10x Genomics, Inc. posted a loss of $0.15 per share, better than expectations for a loss of about $0.25 to $0.27, while revenue of $150.667 million also exceeded estimates near $148 million. The company raised full-year revenue guidance to $625 million-$635 million, above the market view of about $620.8 million. Even so, recent target-price revisions included UBS to $61, Barclays to $70, and BofA to $65, underscoring the post-earnings debate around upside versus valuation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment